PDCD1 and neoplasm: In this study, we checked the robustness of the biomarker under different therapeutic options, namely the presence of an oscillatory pattern of response to therapy in tumours treated with IMS-anti-PD-1 monotherapy and IMS-TMZ/anti-PD-1 combination therapy.